Learn more about the history of Ventinova Medical
From the beginning, we believe in creating a new ventilation concept through revolutionary products. Products that will set a new ventilation standard worldwide, providing substantial benefits in various fields of surgery and promise better ventilation of patients in the operating room. It is our mission to redefine ventilation. Together, we question, we create, we care, we educate, we celebrate. Patient ventilation with minimal impact and maximal control.
In 2004, Dolphys Medical is founded by Dirk van Asseldonk. Development of demand drugs begins.
In 2008, collaboration starts with Prof. Dr. med. Dietmar Enk
In 2010, CE marking of Ventrain
In 2012, CE marking of Cricath
In 2013, Ventinova Medical was founded – 1st investment round
A consortium led by Ventinova, receives 1.9 million Euro’s funding from the European Union’s Horizon 2020 research and innovation programme
In 2016, CE marking of Tritube
In January 2017, first clinical testing of Ventrain and Tritube
In June 2017, Industry Symposium Euroanaesthesia
In August 2017, CE marking of Evone
In October 2017, first in human use Evone
Sign up for our newsletter and we’ll keep you posted about our latest developments.
Prof. Barnes, together with Van Asseldonk and Enk, provide clear theoretical evidence for lower energy dissipation in the lungs by FCV® as compared to VCV or PCV. They present a simple analysis and numerical calculations indicating that energy dissipation may be...
SIGN UP FOR OUR NEWSLETTER: